Hemab Therapeutics Holdings, Inc. IPO - What You Need to Know

Thinking about jumping into the Hemab Therapeutics IPO? Biotech investing is exciting, but these companies can be complex. Here is the breakdown of what you need to know, explained in plain English.

1. What does this company actually do?

Think of Hemab as a "blood specialist" lab. They develop preventative treatments for rare bleeding disorders. Their lead drug, sutacimig, is currently in early-to-mid-stage testing for conditions like Glanzmann thrombasthenia. Their second candidate, HMB-002, is in early development for Von Willebrand Disease. These drugs aim to help patients who currently rely on frequent, risky infusions that often trigger immune reactions.

2. How do they make money and are they growing?

Currently, they make zero profit because they have no products for sale. They are in the research phase, which is essentially a high-stakes science project. They are burning through cash quickly, reporting a loss of $63.9 million for 2025. Their "growth" plan, called "Hemab 2x3 by 2030," aims to have two commercial medicines, two late-stage programs, and two early-stage programs by 2030. Success depends entirely on passing clinical trials and winning government approval.

3. What will they do with the money from this IPO?

Hemab expects to raise about $231 million. They need this cash to fund clinical trials for their two main drugs. They will also spend money on manufacturing, expanding facilities, and general business costs. They believe this cash will last until 2029. However, if trials take longer or costs spike, they could run out of money sooner and need to raise more.

4. What are the main risks I should worry about?

• The "All or Nothing" Risk: They have no approved products. If their two main drugs fail in human trials, the company has no other way to make money.
• The Money Pit: They have lost over $181 million since 2020. They will likely need to raise more cash later, which means issuing more shares. This reduces your ownership percentage in the company.
• Regulatory Hurdles: Regulators like the FDA might demand longer, more expensive studies. This could delay their timeline by years and drain their bank account.
• Tax Complications: Operating in both Denmark and the U.S. creates complex tax risks. If tax authorities challenge their structure, the company could face unexpected fines or penalties.
• Internal Controls: They have identified "material weaknesses" in their financial reporting. They admit their accounting systems were not ready for a public company, which could lead to errors in future financial reports.
• No Track Record: Founded in 2020, the company has never successfully brought a drug to market.

5. Who's running the company?

CEO Dr. Benny Sørensen leads the team. He has deep experience in blood disorders and drug development. The board and leadership team include veterans from major pharmaceutical firms who have successfully launched similar therapies.

6. The Details

• Ticker: "COAG" on the Nasdaq.
• Price Range: $16.00 – $18.00 per share.
• Offering: 15,000,000 shares.

Final Thought for Investors: Investing in a biotech IPO is essentially betting on the success of a scientific experiment. Because Hemab has no revenue and significant financial "growing pains," this is a high-risk play. Before you buy, ask yourself: Am I comfortable with the possibility that this company might need to raise more money (diluting my shares) or that their clinical trials could fail entirely?

Disclaimer: I am an AI, not a financial advisor. Investing in IPOs—especially in biotech—is high-risk. Never invest money you cannot afford to lose, and read the official "Prospectus" on the SEC website before deciding.